{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:38:07Z","timestamp":1762540687660,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2212-0","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T05:56:26Z","timestamp":1507614986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Chalachew","family":"Alemayehu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Aseffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Clavarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McGree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Nikles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"2212_CR1","volume-title":"World population prospect","author":"United Nation","year":"2015","unstructured":"United Nation. World population prospect. 2015."},{"key":"2212_CR2","first-page":"2011","volume-title":"Noncommunicable diseases country profiles","author":"A Alwan","year":"2011","unstructured":"Alwan A, Armstrong T, Cowan M, Riley L, World Health Organization. Noncommunicable diseases country profiles. Geneva: CH; 2011. p. 2011."},{"key":"2212_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-015-0062-9","volume":"15","author":"K Angaw","year":"2015","unstructured":"Angaw K, Dadi AF, Alene KA. Prevalence of hypertension among federal ministry civil servants in Addis Ababa, Ethiopia: a call for a workplace-screening program. BMC Cardiovasc Disord. 2015;15:1.","journal-title":"BMC Cardiovasc Disord"},{"key":"2212_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2261-9-39","volume":"9","author":"F Tesfaye","year":"2009","unstructured":"Tesfaye F, Byass P, Wall S. Population based prevalence of high blood pressure among adults in Addis Ababa: uncovering a silent epidemic. BMC Cardiovasc Disord. 2009;9:1.","journal-title":"BMC Cardiovasc Disord"},{"key":"2212_CR5","volume-title":"Health and health-related indicators, 2008","author":"Ethiopian Ministry of Health","year":"2008","unstructured":"Ethiopian Ministry of Health. Health and health-related indicators, 2008. 2008."},{"key":"2212_CR6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.healthpol.2008.09.018","volume":"90","author":"H H\u00e5konsen","year":"2009","unstructured":"H\u00e5konsen H, Horn AM, Toverud E-L. Price control as a strategy for pharmaceutical cost containment\u2014What has been achieved in Norway in the period 1994\u20132004? Health Policy. 2009;90:277\u201385.","journal-title":"Health Policy"},{"key":"2212_CR7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/00019053-199915060-00001","volume":"15","author":"P Kanavos","year":"1999","unstructured":"Kanavos P, Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics. 1999;15:519\u201333.","journal-title":"Pharmacoeconomics"},{"key":"2212_CR8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/17512433.1.4.497","volume":"1","author":"S Simoens","year":"2008","unstructured":"Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol. 2008;1:497\u2013503.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2212_CR9","first-page":"67","volume":"311","author":"N Fontaine","year":"2001","unstructured":"Fontaine N, Reynders D. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use. Off J Eur Communities L. 2001;311:67\u2013128.","journal-title":"Off J Eur Communities L"},{"key":"2212_CR10","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1023\/A:1013319408893","volume":"18","author":"M-L Chen","year":"2001","unstructured":"Chen M-L, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001;18:1645\u201350.","journal-title":"Pharm Res"},{"key":"2212_CR11","volume-title":"Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority","author":"World Health Organization","year":"1999","unstructured":"World Health Organization. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. 1999."},{"key":"2212_CR12","volume-title":"Pharmacovigalance Report-FMHACA","author":"Food Medicine and Health Care Administration and Control Authority","year":"2010","unstructured":"Food Medicine and Health Care Administration and Control Authority. Pharmacovigalance Report-FMHACA. 2010."},{"key":"2212_CR13","first-page":"121","volume":"7","author":"M Kebede","year":"2015","unstructured":"Kebede M, Borga DK, Bobasa EM. Drug utilization in selected health facilities of South West Shoa Zone, Oromia region, Ethiopia. Drug Healthc Patient Saf. 2015;7:121.","journal-title":"Drug Healthc Patient Saf"},{"key":"2212_CR14","volume-title":"Pharmacy personnel in Hawassa, a facility based cross sectional study. Addis Ababa University","author":"M Sahile","year":"2014","unstructured":"Sahile M. Pharmacy personnel in Hawassa, a facility based cross sectional study. Addis Ababa University. 2014."},{"key":"2212_CR15","volume-title":"Enalapril: MedlinePlus Drug Information","author":"Medicine USNLo","year":"2015","unstructured":"Medicine USNLo. Enalapril: MedlinePlus Drug Information. 2015."},{"key":"2212_CR16","volume-title":"VASOTEC TABLETS (ENALAPRIL) \u2013 FDA","author":"US Food and Drug Administration","year":"2012","unstructured":"US Food and Drug Administration. VASOTEC TABLETS (ENALAPRIL) \u2013 FDA. 2012."},{"key":"2212_CR17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/00004872-199012000-00003","volume":"8","author":"PA Meredith","year":"1990","unstructured":"Meredith PA, Donnelly R, Elliott HL, Howie CA, Reid JL. Prediction of the antihypertensive response to enalapril. J Hypertens. 1990;8:1085\u201390.","journal-title":"J Hypertens"},{"key":"2212_CR18","volume-title":"Standard treatment guideline for primary hospitals","author":"Food Medicine and Health Care Administration and Control Authority","year":"2010","unstructured":"Food Medicine and Health Care Administration and Control Authority. Standard treatment guideline for primary hospitals. Ethiopia: FMHACA; 2010."},{"key":"2212_CR19","volume-title":"Design and implementation of N-of-1 trials: a user\u2019s guide. Agency for healthcare research and quality, US Department of Health and Human Services","author":"R Kravitz","year":"2014","unstructured":"Kravitz R, Duan N. Design and implementation of N-of-1 trials: a user\u2019s guide. Agency for healthcare research and quality, US Department of Health and Human Services. 2014."},{"key":"2212_CR20","doi-asserted-by":"crossref","unstructured":"Nikles J, Mitchell G. The essential guide to N-of-1 trials in health. Dordrecht: Springer Netherlands; 2015.","DOI":"10.1007\/978-94-017-7200-6"},{"key":"2212_CR21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1345\/aph.1G003","volume":"39","author":"JA Pereira","year":"2005","unstructured":"Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann Pharmacother. 2005;39:1188\u201393.","journal-title":"Ann Pharmacother"},{"key":"2212_CR22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5414\/CPP48400","volume":"48","author":"P Pollak","year":"2010","unstructured":"Pollak P. Therapeutically relevant blood pressure differences with two nifedipine (60\u00a0mg) osmotic delivery systems of differing design: three case reports. Int J Clin Pharmacol Ther. 2010;48:400\u20134.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2212_CR23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.HYP.25.2.294","volume":"25","author":"G Chatellier","year":"1995","unstructured":"Chatellier G, Day M, Bobrie G, Menard J. Feasibility study of N-of-1 trials with blood pressure self-monitoring in hypertension. Hypertension. 1995;25:294\u2013301.","journal-title":"Hypertension"},{"key":"2212_CR24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.284.10.1290","volume":"284","author":"GH Guyatt","year":"2000","unstructured":"Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users\u2019 guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users\u2019 guides to patient care. JAMA. 2000;284:1290\u20136.","journal-title":"JAMA"},{"key":"2212_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jclinepi.2010.05.009","volume":"64","author":"J Nikles","year":"2011","unstructured":"Nikles J, Mitchell GK, Schluter P, et al. Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. J Clin Epidemiol. 2011;64:471\u201380.","journal-title":"J Clin Epidemiol"},{"key":"2212_CR26","volume-title":"Clinical trials: a practical guide to design, analysis, and reporting: Remedica","author":"D Wang","year":"2006","unstructured":"Wang D, Bakhai A. Clinical trials: a practical guide to design, analysis, and reporting: Remedica. 2006."},{"key":"2212_CR27","first-page":"217","volume-title":"Pharmacodynamic endpoint bioequivalence studies","author":"P Zou","year":"2014","unstructured":"Zou P, Lawrence XY. Pharmacodynamic endpoint bioequivalence studies. FDA Bioequivalence Standards: Springer; 2014. p. 217\u201341."},{"key":"2212_CR28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0895-4356(96)00429-5","volume":"50","author":"D Zucker","year":"1997","unstructured":"Zucker D, Schmid C, McIntosh M, D\u2019Agostino R, Selker H, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50:401\u201310.","journal-title":"J Clin Epidemiol"},{"key":"2212_CR29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"2212_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-13-104","volume":"13","author":"SA Billingham","year":"2013","unstructured":"Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol. 2013;13:1.","journal-title":"BMC Med Res Methodol"},{"key":"2212_CR31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4269\/ajtmh.14-0683","volume":"93","author":"SN Desai","year":"2015","unstructured":"Desai SN, Akalu Z, Teshome S, et al. A randomized, placebo-controlled trial evaluating safety and immunogenicity of the killed, bivalent, whole-cell oral cholera vaccine in Ethiopia. Am J Trop Med Hyg. 2015;93:527\u201333.","journal-title":"Am J Trop Med Hyg"},{"key":"2212_CR32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407\u201315.","journal-title":"Control Clin Trials"},{"key":"2212_CR33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/HYPERTENSIONAHA.110.162255","volume":"57","author":"P Muntner","year":"2011","unstructured":"Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160\u20136.","journal-title":"Hypertension"},{"key":"2212_CR34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1525-1497.2002.11111.x","volume":"17","author":"M Man\u2010Son\u2010Hing","year":"2002","unstructured":"Man\u2010Son\u2010Hing M, Laupacis A, O\u2019Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med. 2002;17:469\u201376.","journal-title":"J Gen Intern Med"},{"key":"2212_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-10-1","volume":"10","author":"L Thabane","year":"2010","unstructured":"Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1.","journal-title":"BMC Med Res Methodol"},{"key":"2212_CR36","first-page":"249","volume":"10","author":"J Froom","year":"1997","unstructured":"Froom J, Trilling JS, S-s Y, Gomolin IH, Filkin A-M, Grimson RC. Withdrawal of antihypertensive medications. J Am Board Fam Pract. 1997;10:249\u201358.","journal-title":"J Am Board Fam Pract"},{"key":"2212_CR37","first-page":"S41","volume":"9","author":"S Julius","year":"1991","unstructured":"Julius S. Home blood pressure monitoring: advantages and limitations. J Hypertens Suppl. 1991;9:S41\u20136.","journal-title":"J Hypertens Suppl"},{"key":"2212_CR38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(94)91053-7","volume":"344","author":"TG Pickering","year":"1994","unstructured":"Pickering TG. Blood pressure measurement and detection of hypertension. Lancet. 1994;344:31\u20135.","journal-title":"Lancet"},{"key":"2212_CR39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jash.2013.02.005","volume":"7","author":"R Agarwal","year":"2013","unstructured":"Agarwal R, Weir MR. Treated hypertension and the white coat phenomenon: office readings are inadequate measures of efficacy. J Am Soc Hypertens. 2013;7:236\u201343.","journal-title":"J Am Soc Hypertens"},{"key":"2212_CR40","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/01.HYP.6.4.574","volume":"6","author":"HD Kleinert","year":"1984","unstructured":"Kleinert HD, Harshfield GA, Pickering TG, et al. What is the value of home blood pressure measurement in patients with mild hypertension? Hypertension. 1984;6:574\u20138.","journal-title":"Hypertension"},{"key":"2212_CR41","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.amjhyper.2006.12.013","volume":"20","author":"GS Stergiou","year":"2007","unstructured":"Stergiou GS, Argyraki KK, Moyssakis I, et al. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension. Am J Hypertens. 2007;20:616\u201321.","journal-title":"Am J Hypertens"},{"key":"2212_CR42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00004872-199204000-00011","volume":"10","author":"AJ Coats","year":"1992","unstructured":"Coats AJ, Radaelli A, Clark SJ, Conway J, Sleight P. The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens. 1992;10:385\u201391.","journal-title":"J Hypertens"},{"key":"2212_CR43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004872-199102000-00003","volume":"9","author":"S Trazzi","year":"1991","unstructured":"Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens. 1991;9:115\u20139.","journal-title":"J Hypertens"},{"key":"2212_CR44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2288-13-119","volume":"13","author":"A Linden","year":"2013","unstructured":"Linden A. Assessing regression to the mean effects in health care initiatives. BMC Med Res Methodol. 2013;13:119.","journal-title":"BMC Med Res Methodol"},{"key":"2212_CR45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/HYPERTENSIONAHA.110.162123","volume":"57","author":"TJ Niiranen","year":"2011","unstructured":"Niiranen TJ, Johansson JK, Reunanen A, Jula AM. Optimal schedule for home blood pressure measurement based on prognostic data: The Finn-Home Study. Hypertension. 2011;57:1081\u20136.","journal-title":"Hypertension"},{"key":"2212_CR46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/ajh\/hpu216","volume":"28","author":"TJ Niiranen","year":"2015","unstructured":"Niiranen TJ, Asayama K, Thijs L, et al. Optimal number of days for home blood pressure measurement. Am J Hypertens. 2015;28:595\u2013603.","journal-title":"Am J Hypertens"},{"key":"2212_CR47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000150859.47929.8e","volume":"45","author":"TG Pickering","year":"2005","unstructured":"Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142\u201361.","journal-title":"Hypertension"},{"key":"2212_CR48","volume-title":"Good Clinical Practice: consolidated guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (CPMP\/ICH\/135\/95)","author":"Guideline IHT","year":"1997","unstructured":"Guideline IHT. Good Clinical Practice: consolidated guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (CPMP\/ICH\/135\/95). 1997."},{"key":"2212_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-015-1142-y","volume":"17","author":"JP Samuel","year":"2016","unstructured":"Samuel JP, Samuels JA, Brooks LE, et al. Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials. Trials. 2016;17:1.","journal-title":"Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2212-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T05:56:43Z","timestamp":1507615003000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2212-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2212-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2017,10,10]]},"article-number":"470"}}